Esperion Therapeutics (NASDAQ:ESPR) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.36, Bloomberg Earnings reports. During the same period last year, the firm posted ($1.29) EPS.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at $75.79 on Wednesday. The stock has a market capitalization of $1,962.73, a PE ratio of -11.03 and a beta of 2.64. Esperion Therapeutics has a fifty-two week low of $20.39 and a fifty-two week high of $82.18.
In other news, Director Nicole Vitullo sold 11,674 shares of Esperion Therapeutics stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total transaction of $838,076.46. Following the sale, the director now owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 32.50% of the stock is owned by insiders.
Several research firms have recently commented on ESPR. Needham & Company LLC upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and raised their price target for the stock from $72.00 to $81.00 in a research report on Thursday, December 14th. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Credit Suisse Group began coverage on Esperion Therapeutics in a research report on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price target for the company. Finally, Chardan Capital restated a “neutral” rating and set a $75.00 price target (up from $20.00) on shares of Esperion Therapeutics in a research report on Tuesday, December 5th. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $78.23.
COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics (ESPR) Issues Quarterly Earnings Results” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/esperion-therapeutics-espr-issues-quarterly-earnings-results.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.